LONDON (Alliance News) - Angle PLC on Tuesday said researchers at the Cancer Metastasis Laboratory, located at the University of Basel, have provided evidence of circulating tumour cell clusters in glioblastoma.
The liquid biopsy company said the study showed the Parsortix system can detect circulating tumour cells in human glioblastoma.
Using the "simple" blood test, it can analyse and provide molecular characterisation of the cancer.
The research also demonstrated clusters of circulating tumour cells will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.
Prior to that, Angle said it was believed clusters of circulating tumour cells in brain cancers will generally not pass through the blood-brain barrier.
"The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to Angle's own efforts to commercialise the Parsortix system," said Chief Executive Andrew Newland.
"University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course," Newland added.
Shares in Angle were trading 4.4% higher on Tuesday at 48.55 pence each.
Angle (AGL)